Press Release

Phlox Therapeutics raises 1.9M funding to develop RNA therapies for genetic laminopathies The investor syndicate includes ROM Utrecht Region, FIRST Fund, Amsterdam-UMC Ventures and UHSF Funds support preclinical development of Phox’s lead program Naarden, The Netherlands, 6 November 2024 – Phlox Therapeutics (“Phlox”), a private biotechnology company focused on developing innovative RNA-based therapies for cardiomyopathies, […]

Phlox Therapeutics raises additional seed funding to develop RNA therapies for genetic laminopathies Funds will advance the company’s lead program into preclinical development 9 May 2023, Naarden, The Netherlands – Phlox Therapeutics (“Phlox”), a private biotechnology company specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead […]

Company’s technology set to revolutionize the treatment of genetic cardiovascular diseases through its development of RNA-based therapeutics May 2020, Naarden, The Netherlands – Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as it’s initiating director of operations […]